Genetic aspects of familial thyroid cancer

Patrick J Morrison1, A Brew Atkinson

  • 1Regional Medical Genetics Centre, Belfast City Hospital HSC Trust, Belfast BT9 7AB, United Kingdom. patrick.morrison@belfasttrust.hscni.net

The Oncologist
|May 26, 2009
PubMed

Insights

Familial thyroid cancer, though rare, includes well-characterized hereditary medullary thyroid cancer (FMTC) and less understood familial papillary/follicular thyroid cancer (PTC/FTC). This review covers genetic types, clinical features, and screening for these conditions.

Area of Science:

  • Oncology
  • Genetics
  • Endocrinology

Background:

  • Familial thyroid cancer comprises less than 10% of all thyroid cancer cases.
  • Activating germline point mutations in the RET proto-oncogene are linked to multiple endocrine neoplasia types 2A, 2B, and familial medullary thyroid cancer (FMTC).
  • Familial papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) represent a distinct group with less understood genetic predispositions.

Purpose of the Study:

  • To review the genetic types of familial medullary thyroid cancer (FMTC) and familial non-medullary thyroid cancer (FNMTC).
  • To outline the clinical features associated with these familial thyroid cancer subtypes.
  • To describe recommended screening protocols for individuals at risk.

Main Methods:

  • Literature review of genetic mutations and familial thyroid cancer syndromes.
  • Analysis of clinical characteristics reported in familial thyroid cancer cases.
  • Synthesis of current screening guidelines for hereditary thyroid cancer.

Main Results:

  • RET proto-oncogene mutations are key in FMTC and related syndromes.
  • Genetic underpinnings of familial PTC and FTC remain largely uncharacterized.
  • Distinct clinical presentations exist for different familial thyroid cancer types.

Conclusions:

  • While FMTC is well-defined, further research is needed into the genetics of familial PTC and FTC.
  • Understanding genetic predispositions is crucial for targeted screening and early detection.
  • Comprehensive management strategies should address both genetic and clinical aspects of familial thyroid cancer.

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...